Abstract
The role of positron emission tomography (PET) in clinical practice is increasing. Clinical decisions based on PET studies are changing patient management by adding functional information to that obtained from conventional morphologic modalities. Focal areas of abnormally increased fluorodeoxyglucose (FDG) uptake are considered suspicious for malignant disease, as metabolic changes often precede the anatomic changes associated with disease. Disease management depends on the tumor type, extent and aggressiveness of the lesion, and on local and distant metastases. Whole-body FDG PET is becoming a standard procedure for the imaging of cancer, and FDG PET can play a significant role in establishing therapeutic response.
Original language | English (US) |
---|---|
Title of host publication | Clinical PET and PET/CT |
Subtitle of host publication | Principles and Applications |
Publisher | Springer New York |
Pages | 89-97 |
Number of pages | 9 |
ISBN (Electronic) | 9781441908025 |
ISBN (Print) | 1441908013, 9781441908018 |
DOIs | |
State | Published - Oct 1 2013 |
ASJC Scopus subject areas
- General Medicine
- General Biochemistry, Genetics and Molecular Biology